NEW ORLEANS – Astrazeneca plc spinout Entasis Therapeutics Inc. is moving to take on some of the world's toughest infections with a new candidate that it said could be the first oral therapy for drug-resistant gram-negative infections in a decade. The beta-lactamase inhibitor, ETX-0282, is headed into animal testing soon and could enter phase I in early 2018, company executives told BioWorld Today, making it the company's third clinical candidate.